Mineralys Therapeutics, Inc. (MLYS) Misses Q2 EPS by 11c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/28/2026

1. ORCL
2. AVGO
3. CDNS
4. ANT
5. META
6. BA
7. SPY
8. INTC
9. JBLU
10. HOOD

Go back to Mineralys Therapeutics, Inc. (MLYS) Misses Q2 EPS by 11c

Goldman Sachs Reiterates Buy Rating on Mineralys Therapeutics, Inc. (MLYS)

August 14, 2024 5:52 AM EDT

Goldman Sachs analyst Richard Law reiterated a Buy rating and $29.00 price target on Mineralys Therapeutics, Inc. (NASDAQ: MLYS)

The analyst comments "MLYS reported 2Q24 financial results on Tuesday with GAAP EPS of -$0.83. R&D expenses were $39.3M, and G&A were $5.9M. Cash/cash equivalents of ~$311M are expected to provide... More

Stifel Reiterates Buy Rating on Mineralys Therapeutics, Inc. (MLYS)

August 14, 2024 5:23 AM EDT

Stifel analyst Annabel Samimy reiterated a Buy rating and $45.00 price target on Mineralys Therapeutics, Inc. (NASDAQ: MLYS).

The analyst comments "We reiterate our Buy on MLYS, $45 TP. MLYS is proceeding on all fronts to enroll a pivotal program that captures the most comprehensive set... More